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Abstract
Introduction: Elevated levels of circulating estrogens are linked to breast cancer risk among postmenopausal
women but little is known about the importance of estrogen metabolism. A recently developed liquid
chromatography tandem mass spectrometry-based method (LC-MS/MS) measuring a panel of 15 estrogen
metabolites (EM) has been evaluated in one study, linking high levels of 2-pathway metabolites relative to the parent
estrogens to reduced breast cancer risk. We analyzed this panel of EM in a nested case-control study of
postmenopausal breast cancer.
Methods: Between 1977 and 1987, 6,915 women provided blood samples to the Columbia Missouri Serum Bank
and were followed for incident breast cancer through December 2002. We studied 215 postmenopausal breast
cancer cases and 215 matched controls who were postmenopausal and not using exogenous hormones at the
time of blood draw. EM were examined individually, grouped by pathway (hydroxylation at the C-2, C-4 or C-16
positions of the steroid ring) and by ratios of the groupings. Logistic regression models controlling for matching
and breast cancer risk factors were used to calculate quartile-specific odds ratios (ORs) and 95% CIs.
Results: Significant elevated risks were not observed for individual EM, except for quartiles of 16-epiestriol (P trend =
0.07). The OR for total EM, the parent estrogens estrone and estradiol, and 2-pathway catechol EM (2-hydroxyestrone
and 2-hydroxyestradiol) were elevated but the trends were not statistically significant. Among 2-pathway metabolites,
risks for the highest levels of 2-hydroxyestrone-3-methyl ether and 2-methoxyestradiol were reduced; ORs for women in
the highest versus lowest quartiles were 0.57 (95% CI = 0.33 to 0.99) and 0.53 (95% CI = 0.30 to 0.96), respectively.
Overall, women with higher levels of 2-pathway EM had a reduced risk of breast cancer, which remained after
accounting for levels of parent EM, 4-pathway EM and 16-pathway EM (all trends, P <0.11).
Conclusions: Women with more extensive hydroxylation along the 2-pathway may have a reduced risk of
postmenopausal breast cancer. Further studies are needed to clarify the risks for specific EM and complex patterns
of estrogen metabolism. This will require aggregation of EM results from several studies.
Introduction
Elevated levels of circulating estrogens are linked to
postmenopausal breast cancer risk [1], but little is
known about the role of specific estrogen metabolites
(EM) or patterns of estrogen metabolism. Accruing evi-
dence, primarily laboratory based, suggests substantial
differences in the genotoxic, mutagenic, and proliferative
activities of various EM and their contributions to mam-
mary carcinogenesis [2-6]. Most breast cancer epidemio-
logic studies have evaluated immunoassays of only a few
estrogens, specifically, estrone sulfate and the parent
estrogens estrone and estradiol [1]. The development of
a highly sensitive and reliable liquid chromatography
tandem mass spectrometry method that simultaneously
measures a panel of 15 EM in serum [7] has facilitated
the exploration of the roles of individual EM and of
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pathways of estrogen metabolism that, until now, have
not been satisfactorily measured in large population-based
studies. This method measures the parent estrogens
(estrone and estradiol, Figure 1), and their metabolites,
derived through hydroxylation on either the A-ring or
D-ring by cytochrome P450 enzyme isoforms, followed by
methylation. On the A-ring, hydroxylation occurs predo-
minately at the C2 position (2-pathway, Figure 1) and to a
lesser extent, at the C4 position (4-pathway, Figure 1).
Hydroxylation at the 16a position of the D-ring produces
16-pathway metabolites (Figure 1) [8].
Whether a panel of EM provides more discrimination
of risk than conventional immunoassays of only the par-
ent estrogens is not known. To date, the only study
with prospectively collected bloods to have evaluated
postmenopausal breast cancer risks associated with this
panel of EM [8] found that women with high levels of
2-pathway metabolites had a reduced risk of breast can-
cer, as did those with more extensive methylation of the
catechol metabolites (2- and 4-methoxyestrone, and 2-
and 4-methoxyestradiol).
To corroborate these findings, we analyzed this panel
of EM in sera drawn prospectively from participants in
a nested case-control study of postmenopausal breast
cancer identified from the Columbia Missouri Serum
Bank Cohort. For a subset of the study participants, par-
ent estrogens had been measured previously by an indir-
ect radioimmunassay (RIA) [9], which also provided the




The Columbia Missouri Serum Bank was established as
part of the National Cancer Institute’s Biological Markers
Project to identify serum markers of breast cancer, as has
been described previously [9]. In brief, between 1977 and
1987, 6,915 women who were free of cancer other than
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Figure 1 Schematic of estrogen metabolic pathway. Adapted from Fuhrman et al. [8].
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non-melanoma skin cancer and living in or around
Columbia, MO, USA, volunteered to provide blood sam-
ples, with most (90%) donating samples prior to 1980.
Participants were identified through the Breast Cancer
Detection Demonstration Project, the Women’s Cancer
Center Control Program at the University of Missouri
hospital, and the Ellis Fischel Cancer Center. At the time
of blood collection, information was obtained on known
breast cancer risk factors, including age, weight, height,
reproductive and menstrual history, family history of
cancer, medical conditions and drug usage, including oral
contraceptives and menopausal hormone therapy.
Approximately 30% of the women donated multiple sam-
ples over the first 10 years of the study, with collections
occurring on average one year apart. At each collection,
1.1 ml serum was aliquoted into glass vials and stored at
-70°C. This study was approved by the National Cancer
Institute (NCI) Institutional Review Board (IRB) and writ-
ten informed consent was obtained from all participants.
Women were followed in two phases for incident
breast cancer. The first follow-up, ending December
1989, identified 107 postmenopausal breast cancers, 70 of
whom were also postmenopausal at blood collection.
Breast cancer cases were identified by self report from a
mailed questionnaire and medical records from the
University of Missouri Hospital and Ellis Fischel Cancer
Center, Missouri Cancer Registry and Missouri Depart-
ment of Vital Statistics. A number of biomarker studies
were conducted on the breast cancer cases and matched
controls identified in this first follow-up including a
study of serum estrogens and androgens [9] measured by
RIA. In a second follow-up, 6,720 women (97% of the ori-
ginal cohort), who were thought to be alive and without a
history of breast cancer or other cancer in the first fol-
low-up phase, were contacted between 1999 and 2002,
and an additional 197 breast cancer cases were identified.
Thus, a total of 304 incident breast cancer cases were
identified in this cohort, of whom 232 were postmeno-
pausal at the time of blood donation and diagnosis. For
this analysis, we excluded eight cases with limited blood
remaining in the serum bank, seven who did not have a
date of diagnosis, one diagnosed prior to blood draw and
one lost to follow-up in the second phase of the study.
The 215 breast cancer cases included in this study were
individually matched to one of 215 postmenopausal con-
trols who was alive and cancer-free at the age of the case
diagnosis, with matching on type of menopause (natural,
ovariectomy, hysterectomy at age 54 or later, and early
hysterectomy (age <54)); age (+/- five years), season of
blood draw, years since menopause (<1, 1 to <2, 2 to <3,
3 to <4, 4+) and time of day at blood collection (11 am to
1pm, 2 to 5 pm and 7 to 10 pm). Participants who
reported using exogenous hormones at the time of blood
donation were not eligible for this study. Additionally, 65
cases and 48 controls had RIA results for estrone, estra-
diol and estrone sulfate available from the first follow-up
phase [9] and liquid chromatography tandem mass spec-
trometry (LC-MS/MS) assay measurements.
Laboratory methods
Stable isotope dilution LC-MS/MS was used to quanti-
tate15 EM including: estrone, estradiol, 2-pathway
metabolites (2-hydroxyestrone, 2-methoxyestrone, 2-
hydroxyestradiol, 2-methoxyestradiol and 2-hydroxyes-
trone-3-methyl ether); 4-pathway metabolites (4-hydro-
xyestrone, 4-methoxyestrone and 4-methoxyestradiol);
and 16-pathway metabolites (16a-hydroxyestrone, estriol,
17-epiestriol, 16-ketoestradiol and 16-epiestriol). Details of
the method have been published previously [7]. For this
study, six labeled internal standards were used: deuterated
2-hydroxyestradiol, 2-methoxyestradiol and estriol (C/D/N
Isotopes Inc, Pointe-Claire, QC, Canada); deuterated 16-
epiestriol (Medical Isotopes Inc, Pelham, NH, USA); and
13C-labeled estrone and estradiol (Cambridge Isotope
Laboratories, Andover, MA, USA).
In serum, this method detects 15 EM which circulate
primarily as sulfated and/or glucuronidated conjugates.
Beginning with the parent estrogens (estrone and estra-
diol, Figure 1), hydroxylation occurs on the A- or D-ring.
On the A-ring, metabolism proceeds predominately at
the C2 position (2-pathway, Figure 1), producing the
2-pathway catechols: 2-hydroxyestrone and 2-hydroxyes-
tradiol. Methylation of these 2-catechol metabolites
yields the 2-methoxycatechols: 2-methoxyestrone,
2-methoxyestradiol and 2-hydroxyestrone-3-methyl
ether. To a lesser extent, metabolism on the A-ring pro-
ceeds at the C4 position (4-pathway, Figure 1) yielding
the 4-catechol (4-hydroxyestrone) which may be further
methylated to 4-methoxyestrone and 4-methoxyestradiol.
Hydroxylation at the 16a position of the D-ring produces
16-pathway metabolites (Figure 1): 16a-hydroxyestrone,
estriol, 17-epiestriol, 16-ketoestradiol and 16-epiestriol.
All metabolites circulate, at least in part, as sulfated and/
or glucuronidated conjugates to facilitate transport and
excretion, while only five (estrone, estradiol, estriol,
2-methoxyestrone and 2-methoxyestradiol) also circulate
in unconjugated forms. To capture the unconjugated
forms, the serum sample was split into two aliquots, one
to measure the total concentration of each of the 15
metabolites (that is, the sum of conjugated plus unconju-
gated forms); the other, to measure the unconjugated
forms. To measure the sum of the conjugated plus uncon-
jugated forms, an enzyme with sulfatase and glucuronidase
activity is added to the samples to cleave any sulfate and
glucoronide groups from the parent estrogens [7]. To
measure the unconjugated forms only, addition of the
enzyme is not included in the sample preparation steps.
For those metabolites with both total and unconjugated
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measurements, the concentration of the conjugated form
was calculated as the difference between the total and the
unconjugated measurements. Sera from cases and matched
controls were assayed in the same batch. Duplicate quality
control (QC) samples from two women were placed in
each batch, and samples in the batch were randomly
ordered so that laboratory personnel were masked to study
or QC status. Laboratory coefficients of variation were less
than 5% for all individual estrogens and estrogen metabo-
lites measured and less than 3% for estrone, estradiol, and
estriol.
Methodologic studies
In addition to exploring the etiologic role of EM in breast
cancer, this cohort provided a unique opportunity to
address a number of questions, including the temporal
variability of this panel of EM in postmenopausal women
and the comparability of these measurements to other
assay methodologies. To study the first question, sera
from 24 controls who provided bloods at two or more
consecutive, annual screening visits were assayed, with
bloods from each woman measured in the same batch.
Of these, 22 had serum from three blood collections
occurring one year apart; two had two blood collections,
each one year apart. Additionally, we compared levels of
circulating estrone, estradiol and estrone sulfate mea-
sured by RIA [9] to levels of total and unconjugated
estrogen and estradiol obtained by LC-MS/MS in a sub-
set of 68 cases and 45 controls.
Statistical methods, case-control analysis
Initially, the distribution of each EM was analyzed to
identify possible outliers and to apply appropriate data
transformations. Non-parametric models were used to
evaluate median differences in EM levels between cases
and controls. Case-control differences between individual
EM, pathway EM (for each of the 2-, 4- and 16-pathways,
the sum of individual EM in the respective pathway, see
Figure 1) and the ratios of these pathways were explored.
Unconditional logistic regression models were used to
estimate quartile-specific odds ratios (ORs) and 95% CIs
for individual EM, pathway EM and the ratios of the
pathways. ORs controlling for matching factors and
known breast cancer risk factors were calculated, with
confounding addressed by including covariates that chan-
ged the effect estimates by more than 10% in the final
model. The final model included: family history of breast
cancer; body mass index (BMI); age at menarche; parity
and age at first birth; age at blood collection; type of
menopause; years between blood collection and meno-
pause; season; and time of day of blood draw. For each
EM, further adjustment for unconjugated estrone was
made to assess whether levels of a given EM contributed
to risk independent of parent levels; however, this did
not alter OR estimates by >10% and results are not
presented. The magnitude and patterns of risks from
additional analyses, including using conditional logistic
regression models, and excluding the 17 women whose
breast cancer was diagnosed less than two years after
blood donation, were comparable to the reported results
and are not provided. No adjustment was made for mul-
tiple comparisons.
Statistical methods, methodologic studies
We assessed EM consistency within a woman over two
to three years using samples from controls with repeat
blood collections, using nested analysis of variance
(ANOVA) models to calculate the intraclass correlation
coefficients (ICC). Pearson’s correlation coefficients were
used to assess comparability of RIA and LC-MS/MS
measurements of the parent estrogens. All measure-
ments were logarithmically transformed. For all analyses,
all tests of significance were two-tailed and probability
values of <0.05 were considered statistically significant.
Analyses were performed using SYSTAT software [10]
and forest plots were created with STATA [11].
Results
Study population
Table 1 presents the distribution of breast cancer risk fac-
tors and matching characteristics among cases and con-
trols. Cases and controls were similar with respect to most
known breast cancer risk factors including BMI, age at
menarche, a family history of breast cancer, reproductive
history and, among parous women, age at first pregnancy.
However, parous cases had significantly fewer pregnancies
(P <0.05) than parous controls. Most women in this study
were naturally menopausal (71%), with the remaining hav-
ing had an ovariectomy (13%) or hysterectomy (16%). The
mean age at breast cancer diagnosis was 61.8 (range 50.8
to 76.8), with mean follow-up of 11.7 years (range 0.3 to
24.8 years). The age at blood collection for both groups
was similar (mean of 59.4 and 59.8 for cases and controls,
respectively).
EM distributions and correlations
Median and interdecile ranges (10% and 90% percen-
tiles) of each EM are presented for cases and controls
(Table 2). Among all study participants, levels of estriol,
estrone and 2-hydroxyestrone were highest, accounting
for approximately 73% of the total EM in circulation.
Except for 2-methoxyestradiol, EM levels were not sig-
nificantly different between cases and controls.
Among controls, levels of the parent estrogens,
estrone and estradiol, were highly correlated with each
other (rho = 0.75, results not presented); with estrone
catechols (2-hydroxyestrone and 4-hydroxyestrone; rho
ranged from 0.62 to 0.73) and with some 16-pathway
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Table 1 Distribution of cases and controls by breast cancer risk factors and matching characteristics; Columbia
Missouri Serum Bank Cohort Breast Cancer Case-Control Study
Cases Controls
Number % Number %
215 100 215 100
Breast cancer risk factors
Family history of breast cancer
yes 67 31.2 55 25.6 P = 0.199
BMI
<25 89 41.4 95 44.2
25-29 87 40.5 80 37.2
30+ 39 18.1 40 18.6 P = 0.778
Mean (SD) 26.2 (+/- 3.9) 26.5 (+/- 4.8)
Ever smoke
yes 58 27.0 56 26.0 P = 0.270
Age at menarche
<12 28 13.0 30 14.0
12 58 27.0 49 22.8
13 71 33.0 75 34.9
14+ 58 27.0 61 28.4 P = 0.799
Reproductive history
Never pregnant 36 16.7 34 15.8 P = 0.811
Number of prenanciesa
1-2 102 57.0 83 45.9
3-4 57 31.8 66 36.5
5+ 20 11.2 32 17.7 P = 0.002
Age at first pregnancya
<20 24 13.4 34 18.8
20-24 98 54.7 85 47.0
25-29 38 21.2 41 22.7
30+ 19 10.6 21 11.6 P = 0.415
mean (SD) 23.9 (+/- 4.2) 24.2 (+/-4.7)
aamong parous women
Age at menopause
<45 40 18.6 38 17.7
45 to 49 53 24.7 63 29.3
50 to 54 89 41.4 91 42.3
55+ 20 9.3 10 4.7
unknown 13 6.0 13 6.0 P = 0.371
Years to breast cancer diagnosis (from blood draw)
<1 7 3.3
1 to <2 10 4.7
2 to <3 18 8.4




Age at blood collection
<55 60 27.9 62 28.8
55 to 59 58 27.0 49 22.8
60 to 64 45 20.9 43 20.0
65 to 69 33 15.3 35 16.3
70+ 19 8.8 26 12.1
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Table 1 Distribution of cases and controls by breast cancer risk factors and matching characteristics; Columbia Mis-
souri Serum Bank Cohort Breast Cancer Case-Control Study (Continued)
Type of menopause
Natural 154 71.6 152 70.7
Ovariectomy 26 12.1 28 13.0
Hysterectomy after age 54 22 10.2 22 10.2
Early hysterectomy <age 54 13 6.0 13 6.0
Years between menopause and blood collection
<1 6 2.8 6 2.8
1 to <2 15 7.0 17 7.9
2 to <3 10 4.7 8 3.7
3 to <4 9 4.2 9 4.2
4+ 175 81.4 171 79.5
unknown 4 1.9
Time of blood collection
11 am to 1 pm 82 38.1 80 37.2
2 pm to 5 pm 62 28.8 60 27.9
6 pm to 10 pm 71 33.0 71 33.0
unknown 4 1.9
Table 2 Medians and inter-decile ranges, estrogen metabolitesa cases and controls, Columbia MO Serum Bank Cohort
Breast Cancer Study
Cases Controls
Median Inter-decile range Median Inter-decile range
Parent Estrogens 50% 10% 90% 50% 10% 90%
Estrone
total 252.76 108.7 676.4 226.76 96.5 842.7
conjugated 203.25 75.1 577.6 183.25 68.7 741.1
unconjugated 46.62 25.5 85.5 43.47 22.8 97.5
Estradiol
total 26.80 11.4 72.0 22.94 10.1 105.7
conjugated 13.73 5.0 40.8 12.06 4.9 45.2
unconjugated 11.19 4.5 36.3 10.02 4.1 41.3
2-Pathway
2-hydroxyestrone 75.30 64.4 136.5 73.92 64.7 155.0
2-hydroxyestradiol 12.21 12.2 46.3 22.96 12.5 50.3
2-methoxyestrone
total 43.65 7.4 84.2 41.42 22.3 100.4
conjugated 23.85 7.4 55.0 25.15 9.2 59.4
unconjugated 16.38 6.7 43.5 15.33 5.7 42.5
2-methoxyestradiol
total 13.53^ 6.4 29.4 15.68 6.9 37.6
conjugated 9.91^ 3.7 25.7 11.40 4.3 36.0
unconjugated 2.51 1.0 7.9 2.16 0.9 8.0
2-methoxyestrone,3-methyl ether 5.63 1.9 16.9 6.58 2.2 16.5
4-Pathway
4-hydroxyestrone 19.99 14.1 33.2 17.61 13.4 36.7
4-methoxyestrone 3.48 1.0 7.4 3.60 1.3 7.3
4-methoxyestradiol 1.89 1.0 5.3 1.97 1.0 5.5
16-Pathway
16a-hydroxyestrone 37.87 27.8 72.9 37.25 27.5 85.0
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EM (16a-hydroxyestrone, estriol, and 16keto estradiol;
rho ranged from 0.65 to 0.90). Correlations between the
parent estrogens and the methoxycatechols were lower
(rho ranged from 0.22 to 0.43), while correlations
between the methoxycatechols themselves, or between
the methoxycatechols and either the 16-pathway EM or
the 2- and 4-catechols were low to moderate (rho ran-
ged from 0.09 to 0.43).
Odds ratio results
Individual estrogen metabolites
For the parent estrogens, risks for total, conjugated and
unconjugated estrone and conjugated estradiol were ele-
vated in all quartiles relative to the lowest quartile, but no
trends were observed (Figure 2), and only the ORs for the
third quartiles of estrone and of estradiol were statistically
significant.
Among the 2-pathway metabolites (Figure 3), risks for
the catechols (2-hydroxyestrone and 2-hydroxyestradiol)
were non-significantly elevated, while the ORs for some
methoxycatechols were reduced. Higher concentrations of
2-hydroxyestrone, 3-methyl ether and total 2-methoxyes-
tradiol were associated with significantly reduced breast
cancer risk (P trend for both <0.05). ORs for the highest
versus lowest quartiles were 0.57 (95% CI = 0.33 to 0.99)
and 0.46 (95% CI = 0.25 to 0.84) for 2-hydroxyestrone, 3-
methyl ether and total 2-methoxyestradiol, respectively.
Of the 4-pathway metabolites (Figure 4), risks for mod-
erate and high levels of the catechol 4-hydroxyestrone
were not significantly elevated and no trend was appar-
ent. Declining risk for higher levels of 4-methoxyestrone
was suggested (P trend = 0.099).
In the 16-pathway (Figure 5), borderline significant
trends (P = 0.099) of increasing risk with increasing con-
centration were observed for total estriol and 16-epiestriol.
Pathways
For this component of the analysis, EM in a given path-
way was summed. For total EM (sum of all EM) and the
parent estrogens (estrone plus estradiol), ORs were ele-
vated but not significant at all levels and no trends were
observed (Figure 6). Declining risks with increasing levels
of 2-pathway EM were suggested (P trend = 0.099), but
the individual risks were not significant. No associations
were observed for the 4-pathway or 16-pathway EM.
Ratios
Ratios of pathways were studied to explore the relative
contribution of one pathway to breast cancer risk while
accounting for either the precursor estrogens (parent
estrogens) or another pathway. Relative to levels of the
parent EM, women with higher levels of 2-pathway EM
were at lower risk (OR for quartile 4 versus quartile 1 =
0.72 (95% CI = 0.41 to 1.27)), but the trend was not sig-
nificant (P trend = 0.11, Figure 7). Risks for elevated
levels of 4-pathway EM relative to parent EM showed a
similar pattern of non-significantly reduced risks, but the
trend was not significant. No consistent patterns of risk
were observed for the ratios of 16-pathway to parent EM.
ORs for women with high versus low levels of the ratio
of 2-pathway to 4-pathway EM and 2-pathway to 16-
pathway EM were non-significantly reduced and trends
were suggested (P = 0.10, Figure 7; OR highest quartile =
0.60 (95% CI = 0.34 to 1.03) and 0.63 (95% CI = 0.35 to
1.12) for the ratio of 2-pathway to 4-pathway and to 16-
pathway EM, respectively).
ORs for the catechols (sum of 2-hydroxyestrone, 2-
hydroxyestradiol and 4-hydroxyestrone) and methoxyca-
techols (sum of 2-methoxyestrone, 2-methoxyestradiol,
4-methoxyestrone, 4-methoxyestradiol and 2-hydroxyes-
trone, 3-methyl ether) were for the most part not statis-
tically significant, and no trends were observed (data not
shown). No patterns were observed for ratios of the
catechol EM to methoxycatechol EM.
Temporal variability of estrogen metabolites
Overall, among the 24 non-case women with two or
more consecutive annual blood draws, the mean percent
changes from one year to the next for estrone and estra-
diol were modest (2.1% and 8.8%, respectively). However,
temporal differences were observed for the other EM.
The ICCs for estrone and estradiol were relatively high
(72% and 65%, respectively; Additional file 1), while for
the 16-pathway EM, ICCs were moderate (35% to 53%).
Table 2 Medians and inter-decile ranges, estrogen metabolitesa cases and controls, Columbia MO Serum Bank Cohort
Breast Cancer Study (Continued)
Estriol
total 283.29 167.2 580.9 271.98 163.4 624.7
conjugated 245.97 131.8 536.9 227.52 126.4 598.7
unconjugated 32.69 8.1 84.8 26.71 7.8 73.7
16-ketoestradiol 32.05 20.6 64.0 31.59 19.3 76.7
16-epiestriol 5.97 2.3 20.5 5.50 1.9 19.0
17-epiestriol 2.21 1.1 8.1 2.33 1.0 7.5
Total EM 837.91 540.4 1777.9 802.76 512.7 2151.8
apmol/l. ^P <0.05, Wilcoxon rank sum test of differences between cases and controls.
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For the remaining EM in the 2- and 4-pathways, ICCs
were low, ranging from 10% for 2-methoxyestrone to
38% for 2-hydroxyestrone.
Comparison of estrogen levels by RIA and LC-MS/MS
Figure 8 compares levels of total and unconjugated estra-
diol as measured by LC-MS/MS (y axis, top left and right
plots, respectively) against RIA measures of estradiol
(x axis). Pearson’s correlation coefficients were moderately
high, being 0.63 and 0.67, respectively. The bottom plots
compare assay methods for estrone, with the two left plots
comparing LC-MS/MS levels of total and unconjugated
estrone, respectively (y axis) to RIA measured estrone
(x axis) and the right-most plot of total estrone (LC-MS/
MS, y axis) and estrone sulfate (RIA, × axis). Correlations
for total and unconjugated estrone with RIA measured
estrone were slightly weaker (Pearson’s rho = 0.56 and
0.51, respectively) but levels of LC-MS/MS estrone com-
pared favorably with RIA measured estrone sulfate (rho =
0.68).
Discussion
In this nested case-control study of postmenopausal
breast cancer and patterns of estrogen metabolism,
increased risks for individual EM were not observed
except for 16-epiestriol. Risks for estrone, estradiol and
the 2-pathway catechols, 2-hydroxyestrone and 2-hydro-
xyestradiol, were non-significantly elevated at all levels
of exposure, while risk reductions were suggested for
higher levels of some 2-pathway methoxyestrogens,
including 2-hydroxestrone 3-methyl ether, and conjugated
and total 2-methoxyestradiol. Analysis of the pathways
provided information beyond that contributed by parent
estrogens alone since women with higher levels of 2-path-
way EM overall tended to have a reduction in breast can-
cer risk, which persisted even after accounting for the
contribution of their precursor hormones, estrone and
estradiol. Similarly, relative to levels of both 4-pathway
and 16-pathway EM, women with higher levels of 2-path-
way metabolites were at lower, albeit not statistically sig-
nificant, risk than those with low 2-pathway EM. Taken
together, these findings suggest that women with more
extensive estrogen metabolism along the 2-hydroxylation
pathway may have a reduced risk of postmenopausal
breast cancer.
To date, the only study of postmenopausal breast can-
cer to report findings from this panel of estrogens
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Figure 2 Forest plot of OR and 95% CI for parent estrogens. The center mark on each line corresponds to the odds ratio (OR) estimate and
the length of the line corresponds to the confidence interval. Quartile cutpoints are based on the control distribution. For the referent quartile,
only a mark at 1.0 is presented. ORs are adjusted for family history of breast cancer; BMI; age at menarche; parity and age at first birth; age at
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high 2-pathway metabolism [8]. In that study, unlike
ours, high levels of both unconjugated estradiol and
unconjugated estrone were significantly linked to elevated
breast cancer risk. While we found elevated risks for high
levels of unconjugated estrone, no trends were apparent
and no association was observed for unconjugated estra-
diol. Additionally, the ranges of EM values among our
postmenopausal women were much broader than those
observed in the earlier study. Reasons for these differences
are not clear; however, the state of current efforts to study
the relationship between breast cancer risk and various
EM is reminiscent of the early 1990s, when cohort studies
began investigating levels of circulating sex steroid hor-
mones. At that time, studies were relatively small (the
number of cases by cohort ranged from 29 to 310), and
most, but not all, linked elevated estrogens to breast
cancer risk. It was not until results were pooled [1] that
elevated levels of estrone and estradiol were conclusively
linked to a doubling of breast cancer risk. We note that
the ranges and absolute levels of estrone and estradiol in
our study are comparable to levels observed in the studies
that contributed to the pooled analysis, where conven-
tional RIA assays were used [1,12].
Our study had a number of potential limitations. Unlike
most studies of postmenopausal breast cancer, our cases
were not more likely than controls to be overweight or
obese, potentially limiting the generalizability of our find-
ings. In addition, hormone receptor status could only be
obtained on a fraction of the cases in this study. Serum
samples were stored in glass vials at -70°C for more than
30 years and the consequence of such long-term storage
on sex hormones is not known. Sample evaporation and
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2-hydroxyestradiol 
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Figure 3 Forest plot of OR and 95% CI for 2-pathway estrogen metabolites. The center mark on each line corresponds to the odds ratio
(OR) estimate and the length of the line corresponds to the confidence interval. Quartile cutpoints are based on the control distribution. For the
referent quartile, only a mark at 1.0 is presented. ORs are adjusted for family history of breast cancer; BMI; age at menarche; parity and age at
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degradation do not appear to have influenced measured
EM levels in this study, since as discussed, the ranges of
individual EM values were quite broad, and for those
estrogens commonly measured by commercial labora-
tories, absolute levels were consistent with normative
values [13,14]. Ironically, initiating this study in the late
1970s/early 1980s may have been an advantage, since
menopausal hormone therapy was not highly recom-
mended for postmenopausal women at that time.
Although we excluded women currently using exogenous
hormones, our EM values are not likely to have been con-
taminated by recent hormone use. The relatively small
size of this study did limit our power to detect significant
risks for individual EM and to disentangle the effects of
complex patterns of estrogen metabolism. Thus, while it is
not surprising that few of the individual risks or the trends
reached statistical significance, our finding that women
with more extensive 2-pathway metabolism may be at
reduced risk of postmenopausal breast cancer does repli-
cate results from the one previous postmenopausal breast
cancer study of this EM panel [8].
While the primary intent of this study was to evaluate
whether this panel of EM is informative with regard to
breast cancer risk, it is the first study to explore features
of this panel that are pertinent to epidemiologic research.
For instance, in order to reflect adequately a woman’s
long-term adult hormone profile, EM measurements
must be relatively stable from one year to the next. The
year-to-year reproducibility of parent estrogens in post-
menopausal women using RIAs has been conflicting
[15-19], with ICCs ranging from 36% to 68% for estradiol
and from 57% to 74% for estrone. In our study, multiple
blood collections in the first years after enrollment
allowed us to assess the temporal variability of this panel
of EM among controls who contributed two or more
bloods at yearly intervals. Our finding of relatively high
ICCs for estradiol and estrone (≥65%) support the use of
a single measurement by LC-MS/MS to categorize long
term levels of these estrogens in postmenopausal women.
However, for the other EM, where ICCs ranged from
10% to 50%, a single measure may not characterize long-
term levels very well and may have contributed to our
lack of findings for these EM by attenuating the observed
risks. Additionally, in a subset of study participants for
whom estrone and estradiol were measured using both
RIA and LC-MS/MS methods, the levels correlated favor-
ably. Compared to levels of estradiol measured by RIA
where extraction via celite chromatography was applied
before the assay was used [9], levels of total and unconju-
gated estradiol (LC-MS/MS) were well correlated. For
estrone, the correlations were slightly lower, but total
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Figure 6 Forest plot of OR and 95% CI for parent, 2-, 4-, and 16-pathway estrogen metabolite groups. The center mark on each line
corresponds to the odds ratio (OR) estimate and the length of the line corresponds to the confidence interval. Quartile cutpoints are based on
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unconjugated, sulfated and glucuronidated estrone) cor-
related highly with RIA measures of estrone sulfate.
Elevated levels of circulating estrogens have been con-
vincingly linked to breast cancer risk among postmeno-
pausal women [1,18], yet the molecular mechanisms
underlying this link are not entirely clear, and even less is
known about the importance of patterns of estrogen
metabolism or of specific EM in postmenopausal breast
carcinogenesis. Proposed mechanisms underlying this
association include observations that some metabolites
enhance the proliferation of breast epithelial cells
mediated by estrogen receptor activity, and/or act as sub-
strates for conversion into DNA- damaging compounds
[2-4,20,21]. It is well recognized that levels of circulating
estrogens in postmenopausal women, particularly estra-
diol, may be influenced by host characteristics such as
BMI, lifestyle and dietary factors [12,21]; however, it is
not known how or whether these factors alter estrogen
metabolism. The development of laboratory methods to
measure potential DNA-damaging metabolites in sera
from large epidemiologic studies is a step forward in
understanding the mechanisms of estrogen metabolism
in breast carcinogenesis. This may help identify women
who may benefit from strategies that alter estrogen meta-
bolism through lifestyle and/or chemopreventive endo-
crine therapies. For now, it is not clear whether
measuring specific EM provides more insight into breast
cancer etiology than studies relying only on measures of
the parent estrogens alone, although our findings, along
with those from one prior study, suggest that women
with more extensive estrogen metabolism, particularly
along the 2-pathway, may have a reduced risk of postme-
nopausal breast cancer.
Conclusions
Further investigations are needed to corroborate whether
women with more extensive estrogen 2-pathway estrogen
metabolism are at reduced risk of postmenopausal breast
cancer and to identify whether breast cancer risk is asso-
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estrogen metabolism. This will require the aggregation of
EM results from several studies. Additionally, efforts to
replicate the temporal variability of the metabolites are
needed to evaluate whether measures from a single blood
collection are sufficient for meaningful risk assessment.
Additional material
Additional file 1: Intraclass Correlation Coefficients of EM.
Description: Temporal variability in EM measurements from 24
women who donated bloods annually over a three year period.
Abbreviations
ANOVA, analysis of variance; BMI, body mass index; EM, estrogen
metabolites; ICC, intraclass correlation coefficient; IRB, Institutional Review
Board; LC-MS/MS, liquid chromatography-tandem mass spectrometry; NCI,
National Cancer Institute; OR, odds ratio; QC, quality control; RIA:
radioimmunoassay.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All the authors made substantial contributions to the study design, conduct
of the hormone assays or the analysis and interpretation of data. RTF and
GLG conceived and designed the study, coordinated the research, provided
guidance throughout the study process, performed the analysis, participated
in interpretation of the data and drafted the manuscript. XX and TDV carried
out hormone assays. JFD participated in the study design and sample
acquisition, participated in the interpretation of the data and helped draft
the manuscript. LAB and BJF participated in the analysis and interpretation
of the data and helped draft the manuscript. All authors were involved in
revising the manuscript, and have read and approved the final manuscript.
Acknowledgements
The authors thank Dr. Frank Stanczyk, University of Southern California Keck
School of Medicine, for contributing the comparison estrogen
measurements by RIA; and Ms. Lisa Kahle, Information Management Services,
Inc and Ms. Jackie King, BioReliance Corporation for their assistance in the
conduct of the study and data preparation.
Authors’ details
1Hormonal and Reproductive Epidemiology Branch, Division of Cancer
Epidemiology and Genetics, NCI, 6120 Executive Blvd, Bethesda, MD 20852,
USA. 2Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia PA 19111,
USA. 3Department of Epidemiology Fay W Boozman College of Public
Health, University of Arkansas for Medical Sciences, 4301 Markham St #820,
Little Rock, AR 72205, USA. 4Advanced Technology Program, Laboratory of
Pearson’s correlation coefficient=0.632 
Pearson’s correlation coefficient=0.671 
Pearson’s correlation coefficient=0.558 Pearson’s correlation coefficient=0.507 Pearson’s correlation coefficient=0.679 




































































































1 10 100 1,000





















Figure 8 Comparison of estrone and estradiol measurements by LC-MS/MS and RIA. The top graphs compare levels of total and unconjugated
estradiol measured by LC-MS/MS (y axis) to estradiol measured by RIA (x axis). The two leftmost graphs on the bottom compare levels of total and
unconjugated estrone (by LC-MS/MS), respectively, to estrone (by RIA); the rightmost bottom graph compares total estrone (LC-MS/MS) to estrone
sulfate (RIA). All axes are logarithmically scaled. LC-MS/MS, liquid chromatography tandem mass spectrometry; RIA, radioimmunoassay.
Falk et al. Breast Cancer Research 2013, 15:R34
http://breast-cancer-research.com/content/15/2/R34
Page 13 of 14
Proteomics and Analytical Technologies, Frederick National Laboratory for
Cancer Research, SAIC-Frederick, Inc., Frederick MD 21702, USA.
Received: 17 January 2013 Accepted: 22 March 2013
Published: 22 April 2013
References
1. Key TJ, Appleby P, Barnes I, Reeves G, Endogenous Hormones and Breast
Cancer Collaborative Group: Endogenous sex hormones and breast
cancer in postmenopausal women: reanalysis of nine prospective
studies. J Natl Cancer Inst 2002, 94:606-616.
2. Yager JD, Davidson NE: Estrogen carcinogenesis in breast cancer. N Engl J
Med 2006, 354:270-282.
3. Chang M: Dual roles of estrogen metabolism in mammary
carcinogenesis. BMB Rep 2011, 44:423-434.
4. Bolton JL, Thatcher GRJ: Potential mechanisms of estrogen quinine
carcinogenesis. Chem Res Toxicol 2008, 21:93-101.
5. Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, Muti P,
Rogan E, Russo J, Santen R, Sutter T: Catechol estrogen quinines as
initiators of breast and other human cancers: implications for
biomarkers of susceptibility and cancer prevention. Biochem Biophys Acta
2006, 1766:63-78.
6. Cavalieri E, Frenkel K, Liehr JG, Rogan E, Roy D: Estrogens as endogenous
genotoxic agents-DNA adducts and mutations. J Natl Cancer Inst Monogr
2000, 27:75-93.
7. Xu X, Roman JM, Issaq HJ, Keefer LK, Veenstra TD, Ziegler RG: Quantitative
measurement of endogenous estrogens and estrogen metabolites in
human serum by liquid chromatography-tandem mass spectrometry.
Anal Chem 2007, 79:7813-7821.
8. Fuhrman BJ, Schairer C, Gail MH, Boyd-Martin J, Xu X, Sue LY, Buys SS,
Isaacs C, Keefer LK, Veenstra TD, Berg CD, Hoover RN, Ziegler RG: Estrogen
metabolism and risk of breast cancer in postmenopausal women. J Natl
Cancer Inst 2012, 104:326-329.
9. Dorgan JF, Longcope C, Stephenson HE Jr, Falk RT, Miller R, Franz C,
Kayle L, Campbell WS, Tangrea JA, Schatzkin A: Relation of prediagnostic
serum estrogen and androgen levels to breast cancer risk. Cancer
Epidemiol Biomarkers Prev 1996, 5:533-539.
10. Wilkinson L: SYSTAT: The System for Statistics, version 12. Evanston IL:
SYSTAT, Inc; 2010.
11. StataCorp: Stata Software: Release 11: College Station, TX: StataCorp LP.12;
2009.
12. Endogenous Hormones and Breast Cancer Collaborative Group: Circulating
sex hormones and breast cancer risk factors in postmenopausal women:
reanalysis of 13 studies: Br J Cancer 2011, 105:709-722.
13. Kratz A, Ferraro M, Sluss PM, Lewandrowski KB: Laboratory reference
values. N Engl J Med 2004, 351:1548-1563.
14. Stanway SJ, Purohit A, Reed MJ: Measurement of estrone sulfate in
postmenopausal women: comparison of direct RIA and GC-MS/MS
methods for monitoring response to endocrine therapy in women with
breast cancer. Anticancer Res 2007, 27:2765-2767.
15. Toniolo P, Koenig KL, Pasternack BS, Banerjee S, Rosenberg C, Shore RE,
Strax P, Levitz M: Reliability of measurements of total, protein-bound and
unbound estradiol in serum. Cancer Epidemiol Biomarkers Prev 1994,
3:47-50.
16. Cauley JA, Gutai JP, Kuller LH, Powell JG: Reliability and interrelations
among serum sex hormones in postmenopausal women. Am J Epidemiol
1991, 133:50-57.
17. Falk RT, Dorgan JF, Kahle L, Potischman N, Longcope C: Assay
reproducibility of hormone measurements in postmenopausal women.
Cancer Epidemiol Biomarkers Prev 1997, 6:429-432.
18. Hankinson SE, Eliassen AH: Endogenous estrogen, testosterone, and
progesterone levels in relation to breast cancer risk. J Steroid Biochem
Mol Biol 2007, 106:24-30.
19. Hankinson SE, Manson JE, Spiegelman D, Willet QC, Longcope C, Speizer FE:
Reproducibility of plasma hormone levels in postmenopausal women
over a 2-3 year period. Cancer Epidemiol Biomarkers Prev 1995, 4:649-654.
20. Liehr JG: Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev 2000,
21:40-54.
21. Folkerd EJ, Martin L, Kendall A, Dowsett M: The relationship between
factors affecting endogenous oestradiol levels in postmenopausal
women and breast cancer. J Steroid Biochem Mol Biol 2006, 102:250-255.
doi:10.1186/bcr3416
Cite this article as: Falk et al.: Relationship of serum estrogens and
estrogen metabolites to postmenopausal breast cancer risk: a nested
case-control study. Breast Cancer Research 2013 15:R34.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Falk et al. Breast Cancer Research 2013, 15:R34
http://breast-cancer-research.com/content/15/2/R34
Page 14 of 14
